Difference between revisions of "Thyroid cancer, BRAF-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Note: these are biomarker-specific regimens" to "Note: these are regimens tested in biomarker-specific populations") |
|||
| Line 50: | Line 50: | ||
|- | |- | ||
|} | |} | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable" style="width: 100%; text-align:center;" |
| − | !style="width: | + | !style="width: 25%"|Study |
| − | !style="width: | + | !style="width: 25%"|Years of enrollment |
| − | !style="width: | + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
| + | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791845/ Subbiah et al. 2017 (BRF117019)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791845/ Subbiah et al. 2017 (BRF117019)] | ||
| + | |2014-2016 | ||
| style="background-color:#ffffbe" |Phase II, <20 pts in subgroup (RT) | | style="background-color:#ffffbe" |Phase II, <20 pts in subgroup (RT) | ||
| style="background-color:#bfd3e6" |ORR: 63% (95% CI, 35-85) | | style="background-color:#bfd3e6" |ORR: 63% (95% CI, 35-85) | ||
Revision as of 02:28, 22 February 2020
| Section editor | |
|---|---|
 |
Jeena M. Varghese, MBBS MD Anderson Cancer Center Houston, TX |
Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.
2 regimens on this page
2 variants on this page
|
Differentiated thyroid cancer, all lines of therapy
Vemurafenib monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Brose et al. 2016 (NO25530) | Phase II |
Note: this study was in patients with papillary thyroid cancer, only.
Chemotherapy
- Vemurafenib (Zelboraf) 960 mg PO twice per day
Continued indefinitely
References
- NO25530: Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1272-82. Epub 2016 Jul 23. link to original article contains verified protocol link to PMC article PubMed
Anaplastic thyroid cancer, all lines of therapy
Dabrafenib & Trametinib
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence | Efficacy |
|---|---|---|---|
| Subbiah et al. 2017 (BRF117019) | 2014-2016 | Phase II, <20 pts in subgroup (RT) | ORR: 63% (95% CI, 35-85) |
Patients in this subgroup had previously treated anaplastic thyroid cancer with BRAF p.V600E mutation.
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF117019: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article contains verified protocol link to PMC article PubMed